Phase I study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancies.

被引：0
|
作者：
Park, Haeseong
Garrido-Laguna, Ignacio
Naing, Aung
Fu, Siqing
Falchook, Gerald Steven
Piha-Paul, Sarina Anne
Wheler, Jennifer J.
Hong, David S.
Subbiah, Vivek
Tsimberidou, Apostolia Maria
Kaseb, Ahmed Omar
Oki, Yasuhiro
Zinner, Ralph
Patel, Shreyaskumar
Bravo, Vivianne Marie Velez
Fanale, Michelle A.
Meric-Bernstam, Funda
Kurzrock, Razelle
Janku, Filip
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Program 1, Houston, TX 77030 USA
[4] HealthONE, Sarah Cannon Res Inst, Denver, CO USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA
[6] UC San Diego Moores Canc Ctr, La Jolla, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.2584
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2584
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours
    J Martin-Liberal
    M Gil-Martín
    M Sáinz-Jaspeado
    N Gonzalo
    R Rigo
    H Colom
    C Muñoz
    O M Tirado
    X García del Muro
    [J]. British Journal of Cancer, 2014, 111 : 858 - 865
  • [22] Phase I trial of a sequence-specific combination of the HDAC inhibitor, vorinostat (SAHA) followed by doxorubicin in advanced solid tumor malignancies
    Daud, A.
    Schmitt, M.
    Marchion, D.
    Bicaku, E.
    Minton, S.
    Egorin, M.
    Zwiebel, J.
    Chiappori, A.
    Sullivan, D.
    Munster, P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [23] Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours
    Martin-Liberal, J.
    Gil-Martin, M.
    Sainz-Jaspeado, M.
    Gonzalo, N.
    Rigo, R.
    Colom, H.
    Munoz, C.
    Tirado, O. M.
    Garcia del Muro, X.
    [J]. BRITISH JOURNAL OF CANCER, 2014, 111 (05) : 858 - 865
  • [24] A phase I study of the heparanase inhibitor: PI-88 and weekly docetaxel in patients (PTS) with advanced solid malignancies.
    Raj, SKS
    Basche, M
    Gore, L
    Grolnic, S
    Hunt, J
    O'Bryant, CL
    Morrow, M
    Creese, B
    Kangas, M
    Sawlwin, D
    Eckhardt, SG
    Holden, SN
    Holden, SN
    [J]. CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6152S - 6152S
  • [25] Phase I study of triciribine phosphate monohydrate, a specific inhibitor of AKt phosphorylation, in adult patients with advanced hematologic malignancies.
    Ravandi, Farhad
    Lancet, Jeffrey
    Giles, Francis
    Plunkett, William
    Williams, Betsy
    Burton, Michelle
    Faderl, Stefan
    Estrov, Zeev
    Borthakur, Gautam
    Akinsanmi, Lawrence
    Kantarjian, Hagop
    [J]. BLOOD, 2007, 110 (11) : 278A - 278A
  • [26] Phase I and pharmacokinetic study of vorinostat, A histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies
    Ramalingam, Suresh S.
    Parise, Robert A.
    Ramananthan, Ramesh K.
    Lagattuta, Theodore F.
    Musguire, Lori A.
    Stoller, Ronald G.
    Potter, Douglas M.
    Argiris, Athanassios E.
    Zwiebel, James A.
    Egorin, Merrill J.
    Belani, Chandra P.
    [J]. CLINICAL CANCER RESEARCH, 2007, 13 (12) : 3605 - 3610
  • [27] A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies
    William R. Schelman
    Anne M. Traynor
    Kyle D. Holen
    Jill M. Kolesar
    Steven Attia
    Tien Hoang
    Jens Eickhoff
    Zhisheng Jiang
    Dona Alberti
    Rebecca Marnocha
    Joel M. Reid
    Matthew M. Ames
    Renee M. McGovern
    Igor Espinoza-Delgado
    John J. Wright
    George Wilding
    Howard H. Bailey
    [J]. Investigational New Drugs, 2013, 31 : 1539 - 1546
  • [28] A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies
    Schelman, William R.
    Traynor, Anne M.
    Holen, Kyle D.
    Kolesar, Jill M.
    Attia, Steven
    Hoang, Tien
    Eickhoff, Jens
    Jiang, Zhisheng
    Alberti, Dona
    Marnocha, Rebecca
    Reid, Joel M.
    Ames, Matthew M.
    McGovern, Renee M.
    Espinoza-Delgado, Igor
    Wright, John J.
    Wilding, George
    Bailey, Howard H.
    [J]. INVESTIGATIONAL NEW DRUGS, 2013, 31 (06) : 1539 - 1546
  • [29] A phase I study of sirolimus and bevacizumab in patients with advanced malignancies
    Cohen, E. E. W.
    Sharma, M. R.
    Janisch, L.
    Llobrera, M.
    House, L.
    Wu, K.
    Ramirez, J.
    Fleming, G. F.
    Stadler, W. M.
    Ratain, M. J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 (10) : 1484 - 1489
  • [30] USE OF MTOR INHIBITOR SIROLIMUS IN RENAL TRANSPLANTED PATIENTS WITH MALIGNANCIES IN GERMANY
    Naik, Marcel
    Arns, Wolfgang
    Basic, Edin
    Budde, Klemens
    Diekmann, Fritz
    Fischereder, Michael
    Gossmann, Jan
    Gwinner, Wilfried
    Heller, Katharina
    Heyne, Nils
    Juergensen, Jan-Steffen
    Morath, Christian
    Riester, Udo
    [J]. TRANSPLANT INTERNATIONAL, 2017, 30 : 148 - 150
12345